Tag Archive for: Moderna

The experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people aged 12 years and older.

In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna’s Spikevax mRNA COVID shot, the company said.

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has received FDA approval for use in adults aged 60 years and older, marking the first time that an mRNA vaccine has been approved for a disease other than COVID-19. This approval represents a significant development in the field and will likely encourage the use of mRNA technology across other disciplines, says GlobalData.

While the science at ASCO continued to push the boundaries for cancer care, much of the conversation in the hallways revolved around the ever-increasing challenges on translating trial successes into clinical practice.

This year has seen a boom in biopharma mergers and acquisitions, with six acquisitions over a billion dollars so far. In light of the massive revenues pharma companies are generating in the obesity space and the pressure many companies are under from looming loss of exclusivity (LOE) on top drugs, analysts don’t see it slowing down anytime soon.

The companies announced today that their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.

The U.S. government is nearing an agreement to fund a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, the Financial Times reported on Thursday, as an H5N1 outbreak spreads through egg farms and among cattle herds.

In an oral decision, the European patent authority maintained the validity of Moderna’s patent ‘949 which describes and protects specific alterations to mRNA molecules designed to lower its immunogenicity, bypass the immune system and boost its translation in the body—as well as the potential uses of the modified mRNA.

The U.S. drug regulator has pushed back its decision on Moderna’s (MRNA.O) respiratory syncytial virus (RSV) vaccine due to “administrative constraints” and will complete the review by the end of this month, the company said on Friday.

Citing a strategic prioritization by Moderna, Metagenomi announced that the partners have “mutually agreed” to terminate their gene editing agreement.